Skip to Content

Biostar Pharmaceuticals Inc BSPM

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Biostar Pharmaceuticals Inc through its subsidiaries involves in the development, manufacturing, and marketing of pharmaceutical products for a variety of diseases and conditions in the People’s Republic of China where it generates most of its revenues. The company’s products include Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter (OTC) medicine for chronic hepatitis B. The current product line of the company also includes several other OTC products and approximately 15 prescription-based pharmaceuticals. Its products are derived from medicinal herbs that are either grown at its own facility or purchased from the suppliers.

No. 588 Shiji Xi Avenue, Shaanxi Province
Xianyang, 712046
T +86 2933686638
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Sep 30, 2017
Fiscal Year End Dec 31, 2017
Stock Type Distressed
Employees 200